Last reviewed · How we verify

Lapatinib+Capecitabine — Competitive Intelligence Brief

Lapatinib+Capecitabine (Lapatinib+Capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor + fluoropyrimidine chemotherapy. Area: Oncology.

phase 3 Tyrosine kinase inhibitor + fluoropyrimidine chemotherapy HER2, EGFR (lapatinib); thymidylate synthase (capecitabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lapatinib+Capecitabine (Lapatinib+Capecitabine) — Tianjin Hemay Pharmaceutical Co., Ltd. Lapatinib inhibits HER2 and EGFR tyrosine kinases while capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, together targeting HER2-positive breast cancer through dual mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lapatinib+Capecitabine TARGET Lapatinib+Capecitabine Tianjin Hemay Pharmaceutical Co., Ltd phase 3 Tyrosine kinase inhibitor + fluoropyrimidine chemotherapy HER2, EGFR (lapatinib); thymidylate synthase (capecitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor + fluoropyrimidine chemotherapy class)

  1. Tianjin Hemay Pharmaceutical Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lapatinib+Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/lapatinib-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: